

Hellenic Liver Patient Association “Prometheus”

George Kalamitsis

Our Vision

- Hellenic Liver Patient Association “Prometheus” vision is for every single patient to be early diagnosed, to get treated with respect and to have equal access to the finest level of medical care - regardless of their origin, lifestyle and the type or stage of liver disease.

Estimated number of persons per fibrosis stage in Greece (2012)

| | Assessment model of the total number of cases | % With diagnosis | Estimated number of diagnosed cases |
|-----------|---|------------------|-------------------------------------|
| F0 | 33784 | 7.9% | 2655 |
| F1 | 36265 | 7.9% | 2850 |
| F2 | 20606 | 20% | 4121 |
| F3 | 23822 | 30% | 7147 |
| F4-comp. | 16867 | 40% | 6747 |
| F4-decom. | 2101 | 100% | 2101 |
| | | | |
| Σύνολο | 133445 | 19.20% | 25621 |



Estimated diagnosed patients with severe fibrosis / cirrhosis

| | Estimated number of diagnosed cases |
|-----------|-------------------------------------|
| F0 | 2655 |
| F1 | 2850 |
| F2 | 4121 |
| F3 | 7147 |
| F4-comp. | 6747 |
| F4-decom. | 2101 |
| Σύνολο | 25621 |

→ Approximately
16.000

Restriction-criteria

- According to the latest data of EOPYY, patient access to the new therapeutic schemes for hepatitis C is based on 4 criteria.
 1. Patients with liver fibrosis stage f3 or f4 that have failed previous therapeutic schemes
 2. Patients with liver fibrosis stage f4
 3. Patients with decompensated cirrhosis
 4. Patients before or after liver transplantation

How much Greece is paying for new DAA's


| Drug | Price per treatment |
|-------------------|---------------------|
| Sovaldi | 31.698 |
| Daclinz | 24.369 |
| Harvoni | 36.879 |
| Exvira & viekirax | 35.859 |
| Olysio | 22.689 |

Alternatives

Hepatitis C treatment access:
Gilead patent on sofosbuvir partially
maintained following MmM patent opposition

PUBLIC INTEREST = 1

GILEAD = 0



Supreme Court



Thank you!!!

George Kalamitsis

gkalamitsis@gmail.com